Does the 23-valent pneumococcal vaccine protect cochlear implant recipients?

Laryngoscope

Volumn 115, Issue 9, 2005, Pages 1586-1590

  Hey, Christiane ^a   Rose, Markus A ^a   Kujumdshiev, Sandy ^a   Gstoettner, Wolfgang ^a   Schubert, Ralf ^a   Zielen, Stefan ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

23 Valent pneumococcal polysaccharide vaccine; Cochlear implant; Immunogenicity; Meningitis; Pneumococcal conjugate vaccine; Vaccination

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGE; ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BRONCHITIS; CHILD; COCHLEA PROSTHESIS; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; OTITIS MEDIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; COCHLEAR IMPLANTS; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MENINGITIS, PNEUMOCOCCAL; PNEUMOCOCCAL VACCINES; PROSPECTIVE STUDIES; VACCINATION;

EID: 24944547773     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlg.0000171016.82850.41     Document Type: Article

References (22)

1. Green KM, Bhatt YM, Saaed SR, et al. Complications following adult cochlear implantation: experience in Manchester. J Laryngol Otol 2004;118:417-420.
2. Reefhuise J, Honein MA, Whitney CG, et al. Risk of bacterial meningitis in children with cochlear implants. N Engl J Med 2003;349:435-445.
3. Arnold W, Bredberg G, Gstöttner W, et al. Meningitis following cochlear implantation: pathomechanisms, clinical symptoms, conservative and surgical treatments. Otorhinolaryngology 2002;64:382-389.
4. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices. Pneumococcal vaccination for cochlear implant candidates and recipients: updated recommendations of the Advisory Committee on Immunization Practices. MMWR 2003;52:739-740.
5. Zielen S, Thomas L. IgG subclasses. In: Thomas L, ed. Clinical Laboratory Diagnostics. Frankfurt: TH Books Verlagsgesellschaft, 2000;695-698.
6. Hamilton RH. Human IgG subclass measurements in the clinical laboratory. Clin Chem 1987;33:1707-1725.
7. Barra A, Schulz D, Aucoutourier P, et al. Measurement of anti-Haemophilus influenzae type b capsular polysaccharide antibodies by ELISA. J Immunol Methods 1988;115:111-117.
8. Zielen S, Bröker M, Strnad N, et al. Simple determination of polysaccharide specific antibodies by means of chemically modified ELISA plates. J Immunol Methods 1996;193:1-7.
9. Concepcion NF, Frasch CE. Pneumococcal type 22 F polysaccharide adsorption improves the specify of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001;8:266-272.
10. Sanders EAM, Rijkers GT, Kuis W, et al. Defective anti-pneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections. J Allergy Clin Immunol 1993;91:110-119.
11. Cohen NL, Roland JT Jr, Marrinan M. Meningitis in cochlear implant recipients: the North American experience. Otol Neurootol 2004;25:275-281.
12. Reinert RR. Pneumococcal conjugate vaccines: a European perspective. Int J Med Microbiol 2004;294:277-294.
13. Fiore AE, Levine OS, Elliott JA, Facklam RR, Butler JC and the Pneumococcal Sentinel Surveillance Working Group. Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease. Emerg Infect Dis 1999;5:828-831.
14. Black S, Shinefield H. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Eur J Pediatr 2002;161:127-133.
15. 197 among infants with sickle cell disease. Pediatrics 2000;106:965-972.
16. Nachman S, Kim S, King J, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003;112:66-73.
17. King JC Jr, Vink PE, Parley JJ, et al. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 1997;99:575-580.
18. Zielen S, Buhring I, Strnad N, et al. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in non-responders to the 23-valent pneumococcal vaccine. Infect Immun 2000;68:1435-1440.
19. Rose M, Hey C, Kujumdshiev S, et al. Immunogenicity of pneumococcal vaccination of patients with cochlear implants. J Infect Dis 2004;190:551-557.
20. Schubert R, Reichenbach J, Rose M, et al. Immunogenicity of the seven valent pneumococcal conjugate vaccine in patients with ataxia-telangiectasia. Pediatr Infect Dis J 2004;23:269-270.
21. Sorensen RU, Leiva LE, Giangrosso PA, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 1998;17:685-691.
22. Rose M, Hey C, Kujumdshiew S, et al. Risk of bacterial meningitis in CI-recipients. Deutsch Ärztebl 2004;101:1072-1074.